Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT

H. Y. Yhim, K. Kim, Jinseok Kim, H. J. Kang, J. A. Kim, C. K. Min, S. H. Bae, E. Park, D. H. Yang, C. Suh, M. K. Kim, Y. C. Mun, H. S. Eom, H. J. Shin, H. J. Yoon, J. H. Kwon, J. H. Lee, Y. S. Kim, S. S. Yoon, J. Y. Kwak

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The aims of this study were to investigate the outcomes of second salvage auto-SCT and to identify the impacts of a second auto-SCT compared with systemic chemotherapy alone on disease outcome. Data from 48 patients who underwent second auto-SCT were matched to 144 patients (1:3) who received systemic chemotherapy alone from the Korean Myeloma Registry. Groups were matched for nine potential prognostic factors and compared for treatment outcomes. The median age of matching-pairs at relapse was 55.5 years. A total of 156 patients (81%) received vincristine, doxorubicin and dexamethasone induction therapy before the first auto-SCT. Thirty-five patients (73%) in the second auto-SCT group received novel agent-based therapies before the second auto-SCT, and similar proportion in both groups received novel therapies after relapse of front-line auto-SCT. With a median follow-up of 55.3 months, patients who underwent a second auto-SCT had significantly better median OS (55.5 vs 25.4 months, P=0.035). In multivariate analysis for OS, <18 months time to progression after first auto-SCT, International Staging System III and salvage chemotherapy alone were independent predictors for worse OS. The outcomes of second auto-SCT appear to be superior to those of systemic chemotherapy alone. A randomized trial comparing both treatment strategies is required.

Original languageEnglish
Pages (from-to)425-432
Number of pages8
JournalBone Marrow Transplantation
Volume48
Issue number3
DOIs
Publication statusPublished - 2013 Mar 1

Fingerprint

Matched-Pair Analysis
Multiple Myeloma
Drug Therapy
Recurrence
Vincristine
Therapeutics
Doxorubicin
Dexamethasone
Registries
Research Design
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Yhim, H. Y. ; Kim, K. ; Kim, Jinseok ; Kang, H. J. ; Kim, J. A. ; Min, C. K. ; Bae, S. H. ; Park, E. ; Yang, D. H. ; Suh, C. ; Kim, M. K. ; Mun, Y. C. ; Eom, H. S. ; Shin, H. J. ; Yoon, H. J. ; Kwon, J. H. ; Lee, J. H. ; Kim, Y. S. ; Yoon, S. S. ; Kwak, J. Y. / Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT. In: Bone Marrow Transplantation. 2013 ; Vol. 48, No. 3. pp. 425-432.
@article{42dd69c196124581b7d5cc3631eea5af,
title = "Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT",
abstract = "The aims of this study were to investigate the outcomes of second salvage auto-SCT and to identify the impacts of a second auto-SCT compared with systemic chemotherapy alone on disease outcome. Data from 48 patients who underwent second auto-SCT were matched to 144 patients (1:3) who received systemic chemotherapy alone from the Korean Myeloma Registry. Groups were matched for nine potential prognostic factors and compared for treatment outcomes. The median age of matching-pairs at relapse was 55.5 years. A total of 156 patients (81{\%}) received vincristine, doxorubicin and dexamethasone induction therapy before the first auto-SCT. Thirty-five patients (73{\%}) in the second auto-SCT group received novel agent-based therapies before the second auto-SCT, and similar proportion in both groups received novel therapies after relapse of front-line auto-SCT. With a median follow-up of 55.3 months, patients who underwent a second auto-SCT had significantly better median OS (55.5 vs 25.4 months, P=0.035). In multivariate analysis for OS, <18 months time to progression after first auto-SCT, International Staging System III and salvage chemotherapy alone were independent predictors for worse OS. The outcomes of second auto-SCT appear to be superior to those of systemic chemotherapy alone. A randomized trial comparing both treatment strategies is required.",
author = "Yhim, {H. Y.} and K. Kim and Jinseok Kim and Kang, {H. J.} and Kim, {J. A.} and Min, {C. K.} and Bae, {S. H.} and E. Park and Yang, {D. H.} and C. Suh and Kim, {M. K.} and Mun, {Y. C.} and Eom, {H. S.} and Shin, {H. J.} and Yoon, {H. J.} and Kwon, {J. H.} and Lee, {J. H.} and Kim, {Y. S.} and Yoon, {S. S.} and Kwak, {J. Y.}",
year = "2013",
month = "3",
day = "1",
doi = "10.1038/bmt.2012.164",
language = "English",
volume = "48",
pages = "425--432",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

Yhim, HY, Kim, K, Kim, J, Kang, HJ, Kim, JA, Min, CK, Bae, SH, Park, E, Yang, DH, Suh, C, Kim, MK, Mun, YC, Eom, HS, Shin, HJ, Yoon, HJ, Kwon, JH, Lee, JH, Kim, YS, Yoon, SS & Kwak, JY 2013, 'Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT', Bone Marrow Transplantation, vol. 48, no. 3, pp. 425-432. https://doi.org/10.1038/bmt.2012.164

Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT. / Yhim, H. Y.; Kim, K.; Kim, Jinseok; Kang, H. J.; Kim, J. A.; Min, C. K.; Bae, S. H.; Park, E.; Yang, D. H.; Suh, C.; Kim, M. K.; Mun, Y. C.; Eom, H. S.; Shin, H. J.; Yoon, H. J.; Kwon, J. H.; Lee, J. H.; Kim, Y. S.; Yoon, S. S.; Kwak, J. Y.

In: Bone Marrow Transplantation, Vol. 48, No. 3, 01.03.2013, p. 425-432.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT

AU - Yhim, H. Y.

AU - Kim, K.

AU - Kim, Jinseok

AU - Kang, H. J.

AU - Kim, J. A.

AU - Min, C. K.

AU - Bae, S. H.

AU - Park, E.

AU - Yang, D. H.

AU - Suh, C.

AU - Kim, M. K.

AU - Mun, Y. C.

AU - Eom, H. S.

AU - Shin, H. J.

AU - Yoon, H. J.

AU - Kwon, J. H.

AU - Lee, J. H.

AU - Kim, Y. S.

AU - Yoon, S. S.

AU - Kwak, J. Y.

PY - 2013/3/1

Y1 - 2013/3/1

N2 - The aims of this study were to investigate the outcomes of second salvage auto-SCT and to identify the impacts of a second auto-SCT compared with systemic chemotherapy alone on disease outcome. Data from 48 patients who underwent second auto-SCT were matched to 144 patients (1:3) who received systemic chemotherapy alone from the Korean Myeloma Registry. Groups were matched for nine potential prognostic factors and compared for treatment outcomes. The median age of matching-pairs at relapse was 55.5 years. A total of 156 patients (81%) received vincristine, doxorubicin and dexamethasone induction therapy before the first auto-SCT. Thirty-five patients (73%) in the second auto-SCT group received novel agent-based therapies before the second auto-SCT, and similar proportion in both groups received novel therapies after relapse of front-line auto-SCT. With a median follow-up of 55.3 months, patients who underwent a second auto-SCT had significantly better median OS (55.5 vs 25.4 months, P=0.035). In multivariate analysis for OS, <18 months time to progression after first auto-SCT, International Staging System III and salvage chemotherapy alone were independent predictors for worse OS. The outcomes of second auto-SCT appear to be superior to those of systemic chemotherapy alone. A randomized trial comparing both treatment strategies is required.

AB - The aims of this study were to investigate the outcomes of second salvage auto-SCT and to identify the impacts of a second auto-SCT compared with systemic chemotherapy alone on disease outcome. Data from 48 patients who underwent second auto-SCT were matched to 144 patients (1:3) who received systemic chemotherapy alone from the Korean Myeloma Registry. Groups were matched for nine potential prognostic factors and compared for treatment outcomes. The median age of matching-pairs at relapse was 55.5 years. A total of 156 patients (81%) received vincristine, doxorubicin and dexamethasone induction therapy before the first auto-SCT. Thirty-five patients (73%) in the second auto-SCT group received novel agent-based therapies before the second auto-SCT, and similar proportion in both groups received novel therapies after relapse of front-line auto-SCT. With a median follow-up of 55.3 months, patients who underwent a second auto-SCT had significantly better median OS (55.5 vs 25.4 months, P=0.035). In multivariate analysis for OS, <18 months time to progression after first auto-SCT, International Staging System III and salvage chemotherapy alone were independent predictors for worse OS. The outcomes of second auto-SCT appear to be superior to those of systemic chemotherapy alone. A randomized trial comparing both treatment strategies is required.

UR - http://www.scopus.com/inward/record.url?scp=84875222958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875222958&partnerID=8YFLogxK

U2 - 10.1038/bmt.2012.164

DO - 10.1038/bmt.2012.164

M3 - Article

VL - 48

SP - 425

EP - 432

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -